newsfilter
← Latest News
Business Wire·

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

-Primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24 -Favorable safety and tolerability profiles observed - Full results to be presented in a late-breaking poster